Investors who don’t agree with your overzealous, or “NP view,” of a buyout # aren’t pharma moles. They are likely investors who see an excellent return at $25.

Could the stock go to $50? Maybe. Could it also go back to .30? Yes. We ar where to discuss both possibilities and make the best decision.